US 7,320,959 B2 | ||
Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease | ||
Mark Anderson, Iowa City, Iowa (US) | ||
Assigned to Vanderbilt University, Nashville, Tenn. (US) | ||
Appl. No. 10/491,323 PCT Filed Oct. 01, 2002, PCT No. PCT/US02/31496 § 371(c)(1), (2), (4) Date Jul. 16, 2004, PCT Pub. No. WO03/029428, PCT Pub. Date Apr. 10, 2003. |
||
Claims priority of provisional application 60/328010, filed on Oct. 08, 2001. | ||
Claims priority of provisional application 60/326576, filed on Oct. 01, 2001. | ||
Prior Publication US 2004/0266675 A1, Dec. 30, 2004 | ||
Int. Cl. A61K 61/00 (2006.01); A01N 25/00 (2006.01) |
U.S. Cl. 514—12 [514/789] | 29 Claims |
1. A method of treating myocardial contractile dysfunction after myocardial infarction in a subject, comprising administering to the subject an effective amount of an inhibitor of Calmodulin Kinase II (CaMKII), whereby the administration of the inhibitor treats post-myocardial infarction myocardial contractile dysfunction in the subject. |